i
Interim influenza vaccination recommendations — 2004–05 influenza season
-
March 18, 2004,
[PDF-1.25 MB]
Details:
-
Corporate Authors:
-
Description:October 5, 2004 10:25 EDT (10:25 PM EDT)
CDCHAN-00214-04-10-05-ADV-N
On October 5, 2004, CDC was notified by Chiron Corporation that none of its influenza vaccine (Fluvirin®) would be available for distribution in the United States for the 2004–05 influenza season. The company indicated that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, where Chiron’s Fluvirin vaccine is produced, has suspended the company’s license to manufacture Fluvirin vaccine in its Liverpool facility for 3 months, preventing any release of this vaccine for this influenza season. This action will reduce by approximately one half the expected supply of trivalent inactivated vaccine (flu shot) available in the United States for the 2004–05 influenza season.
The remaining supply of influenza vaccine expected to be available in the United States this season is nearly 54 million doses of Flu zone® (inactivated flu shot) manufactured by Aventis Pasteur, Inc. Of these doses, approximately 30 million doses already have been distributed by the manufacturer. In addition, approximately 1.1 million doses of live attenuated influenza vaccine (LAIV/Flu Mist®) manufactured by MedImmune will be available this season.
Because of this urgent situation, CDC, in coordination with its Advisory Committee for Immunization Practices (ACIP), is issuing interim recommendations for influenza vaccination during the 2004–05 season. These interim recommendations were formally recommended by ACIP on October 5, 2004, and take precedence over earlier recommendations.
-
Subjects:
-
Series:
-
Document Type:
-
Place as Subject:
-
Location:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Supporting Files
-
No Additional Files
More +
Email
CDC-INFO
